RU96110610A - COMPOSITION - DRUG FORM OF ANTIARTONIC MEANS OF GLUCOSAMINE HYDROCHLORIDE FOR DOMESTIC USE - Google Patents
COMPOSITION - DRUG FORM OF ANTIARTONIC MEANS OF GLUCOSAMINE HYDROCHLORIDE FOR DOMESTIC USEInfo
- Publication number
- RU96110610A RU96110610A RU96110610/14A RU96110610A RU96110610A RU 96110610 A RU96110610 A RU 96110610A RU 96110610/14 A RU96110610/14 A RU 96110610/14A RU 96110610 A RU96110610 A RU 96110610A RU 96110610 A RU96110610 A RU 96110610A
- Authority
- RU
- Russia
- Prior art keywords
- glucosamine hydrochloride
- composition
- granules
- mass
- antiartonic
- Prior art date
Links
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 title claims 4
- 229960001911 glucosamine hydrochloride Drugs 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008187 granular material Substances 0.000 claims 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 229920001277 pectin Polymers 0.000 claims 2
- 235000010987 pectin Nutrition 0.000 claims 2
- 239000001814 pectin Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000207199 Citrus Species 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940124347 antiarthritic drug Drugs 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Claims (1)
в таблетки - аэросил, крахмал, кислота стеариновая, ПВП, с варьированием вспомогательных веществ в пределах 15% при следующем исходном содержании компонентов в прописях по массе и мас.%:
Глюкозамина гидрохлорид - 300 мг (75%)
Вспомогательные вещества - 100 мг (25%)
в том числе:
Аэросил - 26,0 мг (6,5%)
Крахмал - 60,5 мг (15,12%)
Кислота стеариновая - 3,5 мг (0,88%)
Поливинилпиролидон высокомолекулярный - 10,0 мг (2,50%)
при общей массе таблетки - 400,0 мг (100%)
в гранулы - пектин и сахароза при следующем содержании компонентов:
Глюкозамина гидрохлорид - 25,0 г (50%)
Пектин цитрусовый или яблочный - 12,5 (25%)
Сахарная пудра - 12,5 г (25%)
при общей массе гранул в склянке - 50,0 г (100%)юComposition - anti-arthritic drug dosage form in tablets and granules for internal use, characterized in that it contains the active substance glucosamine hydrochloride, to maintain its stability during manufacture and storage, to facilitate the manufacture of auxiliary form, additional substances are introduced:
tablets - aerosil, starch, stearic acid, PVP, with varying auxiliary substances within 15% with the following initial content of components in the mass and mass% prescriptions:
Glucosamine hydrochloride - 300 mg (75%)
Excipients - 100 mg (25%)
including:
Aerosil - 26.0 mg (6.5%)
Starch - 60.5 mg (15.12%)
Stearic acid - 3.5 mg (0.88%)
Polyvinylpyrolidone high molecular weight - 10.0 mg (2.50%)
with a total tablet weight of 400.0 mg (100%)
in granules - pectin and sucrose with the following content of components:
Glucosamine hydrochloride - 25.0 g (50%)
Citrus or Apple Pectin - 12.5 (25%)
Sugar powder - 12.5 g (25%)
with a total mass of granules in the flask - 50.0 g (100%) S
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU96110610A RU2130310C1 (en) | 1996-05-28 | 1996-05-28 | Composition - drug of antiarthrosis agent glucoseamine hydrochloride for oral administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU96110610A RU2130310C1 (en) | 1996-05-28 | 1996-05-28 | Composition - drug of antiarthrosis agent glucoseamine hydrochloride for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU96110610A true RU96110610A (en) | 1998-10-27 |
| RU2130310C1 RU2130310C1 (en) | 1999-05-20 |
Family
ID=20181116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU96110610A RU2130310C1 (en) | 1996-05-28 | 1996-05-28 | Composition - drug of antiarthrosis agent glucoseamine hydrochloride for oral administration |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2130310C1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101545268B1 (en) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | Tablet and method of preparing the same |
-
1996
- 1996-05-28 RU RU96110610A patent/RU2130310C1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3509581B1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| Desai et al. | A floating controlled-release drug delivery system: in vitro-in vivo evaluation | |
| KR880004804A (en) | Spray Dried Acetaminophen | |
| Prakash Rao et al. | Development of gastro retentive drug delivery system of cephalexin by using factorial design | |
| CN100417383C (en) | A kind of effervescent tablet containing cefixime and its preparation method | |
| ES2310686T3 (en) | COMPOSITIONS OF CONTROLLED RELEASE. | |
| RU2001110355A (en) | NON-INFLUENCE OF FOOD PHARMACEUTICAL DOSED DRUG FORMS OF LONG-TERM ACTION CONTAINING MANY UNITS, AND METHOD FOR PRODUCING THEM | |
| GB2329334A (en) | Cholesterol-lowering agents | |
| Kumar et al. | Fast dissolving tablets: waterless patient compliance dosage forms | |
| KR20050083827A (en) | Sustained release l-arginine formulations and methods of manufacture and use | |
| RU2001117518A (en) | COMPOSITIONS CONTAINING CEFUROXYMAXETHYL | |
| ES2607447T3 (en) | Pharmaceutical form for the release of active ingredients | |
| PS et al. | Formulation and evaluation of mouth dispersible tablets of amlodipine besylate | |
| HU191738B (en) | Process for producing retard compositions containing acetylsalicylic acid | |
| RU96110610A (en) | COMPOSITION - DRUG FORM OF ANTIARTONIC MEANS OF GLUCOSAMINE HYDROCHLORIDE FOR DOMESTIC USE | |
| EP1496868A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| AU638586B2 (en) | A tablet and granulate containing mesna as active substance | |
| Singh et al. | Evaluation of acrylamide grafted moth bean starch as controlled release excipient | |
| ES2266494T3 (en) | COMBINED FORMULATION FOR THE TREATMENT OF THE MELLIT DIABETES. | |
| RU2166937C1 (en) | Paracetamol-base drug | |
| KR19990009382A (en) | Alginate beads for sustained release pharmaceutical delivery system using alginic acid and preparation method thereof | |
| RU2467766C1 (en) | Peroral system of medication delivery into intestine region | |
| CN1485034A (en) | Rifaximin suspension mix granule formulation | |
| KR960000429B1 (en) | Sustained-release / rapid-release pharmaceutical complex capsules for oral administration of nitrofurantoin | |
| RU2003132049A (en) | PHARMACEUTICAL COMPOSITION Possessing Cerebrovasodilating and Nootropic Activity |